Loading...
XNAS
VRCA
Market cap74mUSD
Jul 11, Last price  
0.81USD
1D
-7.55%
1Q
66.65%
IPO
-95.64%
Name

Verrica Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
9.86
EPS
Div Yield, %
Shrs. gr., 5y
15.78%
Rev. gr., 5y
%
Revenues
8m
+47.66%
0000012,000,0009,032,0005,124,0007,566,000
Net income
-77m
L+14.31%
-1,913,000-4,459,000-20,648,000-27,950,000-45,497,000-38,903,000-27,678,000-66,995,000-76,579,000
CFO
-61m
L+57.94%
-1,611,000-4,583,000-17,874,000-27,408,000-30,207,000-27,582,000-18,650,000-38,577,000-60,927,000
Earnings
Aug 12, 2025

Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
IPO date
Jun 15, 2018
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
7,566
47.66%
5,124
-43.27%
9,032
-24.73%
Cost of revenue
13,693
21,041
30,328
Unusual Expense (Income)
NOPBT
(6,127)
(15,917)
(21,296)
NOPBT Margin
Operating Taxes
3,191
Tax Rate
NOPAT
(6,127)
(15,917)
(24,487)
Net income
(76,579)
14.31%
(66,995)
142.05%
(27,678)
-28.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
39,637
30,300
26,901
BB yield
-109.30%
-9.13%
-28.63%
Debt
Debt current
13,605
1,400
297
Long-term debt
34,352
47,446
2,755
Deferred revenue
Other long-term liabilities
2,648
Net debt
1,628
(20,701)
(31,221)
Cash flow
Cash from operating activities
(60,927)
(38,577)
(18,650)
CAPEX
(27)
(362)
(302)
Cash from investing activities
(19)
(362)
54,041
Cash from financing activities
37,728
74,213
(16,870)
FCF
(5,091)
(12,246)
(25,976)
Balance
Cash
46,329
69,547
34,273
Long term investments
Excess cash
45,951
69,291
33,821
Stockholders' equity
(307,018)
(230,444)
(163,449)
Invested Capital
345,745
296,417
205,008
ROIC
ROCE
EV
Common stock shares outstanding
51,808
45,342
34,163
Price
0.70
-90.44%
7.32
166.18%
2.75
-69.98%
Market cap
36,266
-89.07%
331,907
253.28%
93,949
-62.08%
EV
37,894
311,206
62,728
EBITDA
(4,858)
(15,081)
(20,578)
EV/EBITDA
Interest
9,412
3,962
2,172
Interest/NOPBT